Nama's AI scorecard currently rates Doximity Buy (7.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is DOCS's P/E ratio?

Doximity trades at a trailing price-to-earnings ratio of 23.7.

When does DOCS report earnings?

Doximity's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $0.42.

What is the DOCS price target?

The median analyst price target from 18 analysts is $29.50, with a range of $18.00 – $47.00.

Is DOCS Shariah compliant?

Nama's AAOIFI-style screen reads Doximity as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Doximity (DOCS)

Healthcare · Health Information Services · NYSE

Doximity (DOCS) is a Healthcare company in the Health Information Services industry. It has a market capitalization of $5.79B, a trailing price-to-earnings ratio of 23.7 and a free-cash-flow yield of 4.9%. Over the most recent reported fiscal year, revenue grew 13.1% and free cash flow per share grew 20.3%. Nama's AI scorecard rates it Buy, 7.9 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 7.9/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Trailing · -55.8% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-61.9%

How far the last close sits under the highest price of the past five years.

Market cap	$5.79B
Trailing P/E	23.7
Price / book	6.4
Price / sales	8.8
FCF yield	4.9%
Dividend yield	—
Gross margin	88.1%
Operating margin	29.6%
Net margin	25.5%
Revenue growth (YoY)	+13.1%
Revenue growth (3-yr annual)	+15.4%
EPS growth (YoY)	+8.5%
FCF/share growth (YoY)	+20.3%
Beta	1.2
Exchange	NYSE
Sector	Healthcare
Industry	Health Information Services

DOCS earnings

Next report: Feb 4, 2027 (Q3 2027, EPS estimate $0.42). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2027	Nov 5, 2026	$0.36	$0.35	+2.9%	—
Q1 2027	Aug 6, 2026	$0.29	$0.30	-3.3%	$156.62M
Q4 2026	May 13, 2026	$0.26	$0.28	-7.1%	$145.37M
Q3 2026	Feb 5, 2026	$0.46	$0.45	+2.2%	$185.05M

DOCS analyst price target

Median target $29.50 from 18 analysts, ranging $18.00 – $47.00.

Health Information Services peers

Ticker	Company	Market cap	P/E
VEEV	Veeva Systems	$49.18B	35.0
TEM	Tempus AI	$13.87B	—
BTSG	BrightSpring Health Services	$13.36B	39.3
HNGE	Hinge Health	$9.34B	51.7
HQY	HealthEquity	$8.57B	23.3
TXG	10x Genomics	$7.72B	296.4
WAY	Waystar	$5.45B	17.2
HTFL	Heartflow	$4.56B	—

Explore live DOCS data on Nama Insights →

Recent Congressional trades

Doximity trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Jonathan Jackson	House	Sell	$15,001 - $50,000	Dec 5, 2025
Jonathan Jackson	House	Buy	$15,001 - $50,000	Sep 23, 2025

DOCS FAQ

Is DOCS a buy?: Nama's AI scorecard currently rates Doximity Buy (7.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is DOCS's P/E ratio?: Doximity trades at a trailing price-to-earnings ratio of 23.7.
When does DOCS report earnings?: Doximity's next scheduled report is on Feb 4, 2027. Analysts expect EPS of $0.42.
What is the DOCS price target?: The median analyst price target from 18 analysts is $29.50, with a range of $18.00 – $47.00.
Is DOCS Shariah compliant?: Nama's AAOIFI-style screen reads Doximity as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.